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Abstract: Cognitive flexibility is the ability to adjust behavior to changes in the environment or task conditions. Previous research sug-
gested that serotonin (5-HT) is involved in cognitive flexibility. Disturbed 5-HT functioning in animals, psychiatric patients and healthy 
volunteers leads to more rigid behavior. A well recognized method to manipulate levels of brain 5-HT is acute tryptophan depletion 
(ATD). This method induces a transient and reversible lowering of plasma tryptophan that has been shown to result in decreased brain 5-
HT. Only recently has ATD research been combined with functional Magnetic Resonance Imaging (fMRI). In this review, we discuss re-
cent investigations into the effect of ATD on the Blood Oxygen Level Dependent (BOLD) response during tasks that require cognitive 
flexibility, in healthy volunteers. 
Functional MRI studies have shown that ATD changes brain activation during tasks that require cognitive flexibility. It is hypothesized 
that ATD changes the processing of negative feedback, rather than impairing response inhibition, impairing the response to an error or 
the loss of cognitive control during response interference. Although the results of these studies are intriguing, they are sometimes contra-
dictory. This could be the result of the different paradigms that have been used. Importantly, these studies strongly suggest that future 
multidisciplinary research should evaluate the mechanisms underlying individual differences and control for variables that have been 
shown to interact with the effect of ATD on cognitive flexibility and the related brain activation.  
Keywords: Serotonin, acute tryptophan depletion, cognitive flexibility, functional neuroimaging. 
Cognitive flexibility refers to the ability to switch between be-
havioral strategies, when changes in the environment lead to altera-
tions in the outcome of actions. Previous research suggests that 
serotonin (5-HT) is involved in cognitive flexibility. Animal re-
search showed that low 5-HT leads to inflexible behavior during 
reversal learning and response inhibition [1-4]. Furthermore, psy-
chiatric disorders that show abnormal 5-HT functioning, such as 
major depression and obsessive compulsive disorder (OCD), are 
associated with rigid behavior [5-7]. Acute tryptophan depletion 
(ATD) is a well-established method to temporarily lower central 5-
HT. Some studies have shown that ATD impairs cognitive flexibil-
ity in healthy volunteers [8-11].  
Although previous research suggests that 5-HT is important for 
cognitive flexibility, it is largely unknown how disturbed 5-HT 
levels change brain activation during tasks that require flexible 
behavior. Neuroimaging techniques such as functional Magnetic 
Resonance Imaging (fMRI) and positron emission tomography 
(PET) are used to investigate which brain areas are activated during 
task performance. These techniques will enable us to gain more 
insight into the effect of disturbed 5-HT functioning on brain acti-
vation associated with task performance. Thus far only a small 
number of studies have investigated the effect of ATD on brain 
activation during tasks that require cognitive flexibility. Based on 
these studies we will hypothesize that ATD impairs cognitive flexi-
bility by affecting negative feedback processing. 
This review is an overview of multidisciplinary en multidimen-
sional research: a combination of chemistry, neurobiology and cog-
nitive neuroscience. A review that discusses these different aspects 
and focuses on the neuropsychological aspects is relevant for the 
understanding of this emerging field of research.  
1. ACUTE TRYPTOPHAN DEPLETION 
In this section we will discuss the method of ATD and its effect 
on the 5-HT system. The neurotransmitter 5-HT cannot cross the  
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blood-brain barrier (BBB) and therefore, its synthesis in the central 
nervous system (CNS) is dependent on its precursors, i.e. trypto-
phan (TRP) and 5-hydroxytryptophan (5-HTP). The amino acid 
TRP is hydroxylated to 5-HTP by the enzyme TRP hydroxylase 
(EC 1.13.99.3). This enzyme has a low affinity for TRP and is un-
der normal physiological conditions not saturated with TRP, and 
thus its activity is dependent on the (central) availability of this 
amino acid [12]. An effective way to lower central 5-HT synthesis 
is by using a dietary amino acid load which does not include TRP, 
but does include a mixture of amino acids, which compete with 
TRP for the BBB [13]. This method is called ATD and has been 
used as a model for depression in order to gain more insight into the 
etiology and symptoms of depression [14-16]. 
Acute dietary depletion of TRP markedly reduces brain 5-HT 
content and this effect is accomplished by a dramatic decrease of 
the flux of TRP from blood to brain, which is caused by virtue of 
the property of the carrier protein that transports only large neutral 
amino acids (LNAA) across the BBB. This protein binds and ac-
tively transports the following LNAA: TRP, tyrosine, phenyla-
lanine, valine, leucine and isoleucine, which compete with each 
other for BBB transport [13]. The rate of passage of TRP across the 
BBB is therefore dependent on the relative peripheral availability of 
TRP versus the other LNAA, expressed as the TRP/LNAA ratio 
[17]. When a TRP-free amino acid drink of 15 amino acids is given 
to healthy male volunteers, reductions of plasma free and total TRP 
levels of 45-91%, depending on the dosage, were caused within 5-7 
h after ingestion of this mixture [18, 19]. The change in total as well 
as free TRP/LNAA ratio was even higher [20]. The primary 
mechanism for depleting brain TRP after a load of this amino acid 
drink is the increase in protein synthesis by the liver resulting in a 
decrease of peripheral TRP stores. This has been substantiated by 
experiments with rats, which showed that ATD reduced serum and 
brain TRP levels and levels of the 5-HT metabolite 5-
hydroxyindoleacetic acid (5-HIAA) [21]. Other animal experiments 
have confirmed that ATD also reduces synthesis and release of 5-
HT in the CNS [22]. Experiments that compared ATD with deple-
tion with the amino acid lysine showed that ATD is specific for 5-
HT metabolism in CNS and that this procedure did not affect brain 
protein synthesis in general [23]. In humans, one of the first studies 
providing evidence for a decline in the rate of 5-HT induced by 
2    Current Medicinal Chemistry,  2007, Vol. 14, No. 17 Evers et al. 
ATD in the brain was by PET using specific radiolabelled precur-
sors [24].  
Other studies investigated the effect of ATD on the 5-HT trans-
porter and 5-HT receptors. Two human PET studies showed that 
ATD did not affect the binding potential of the 5-HT transporter 
[25, 26] and the 5-HT1A receptor [27]. A PET study by Yatham et 
al. [28] showed that ATD decreased the binding potential of the 5-
HT2 receptor in various cortical regions. These studies suggest that 
ATD might decrease cortical 5-HT2 receptor density in humans. A 
rat study by Cahir et al. [29], however, showed that ATD did not 
affect 5-HT2A binding (cortex and striatum). Furthermore, they 
showed that ATD reduced 5-HT1A binding in the dorsal raphe, but 
did not change the post synaptic 5-HT1A binding. Interestingly, 
Lieben et al. [30] showed that the 5-HT6 antagonist Ro4368554 
reversed memory deficits induced by ATD in rats. Obviously, these 
effects of ATD need to be replicated and more research is needed to 
examine the effect of ATD on the 5-HT system.  
2. OPERATIONAL PARADIGMS OF COGNITIVE FLEXI-
BILITY 
Different operational paradigms have been used to study cogni-
tive flexibility. Typically, these tasks require the subjects to choose 
an appropriate response, and adjust the response strategy based on 
feedback. Task that have been used to measure cognitive flexibility 
are reversal learning, decision making, gambling and the intra-
dimensional/extra dimensional (ID/ED) shift task.  
In cognitive flexibility a number of cognitive subprocesses are 
involved. A disturbance in one of these subprocesses is likely to 
impair cognitive flexibility. Cognitive subprocesses involved are 
among others response inhibition (hold back a response to the pre-
viously rewarded stimuli), the ability to overcome response inter-
ference (ignore competing response tendencies) and feedback proc-
essing (reward or punishment signals). In the studies discussed in 
this review response inhibition was studied by a Go/NoGo or a Stop 
Signal task and response interference by a Stroop task. Feedback 
processing was studied by tasks in which feedback is given, such as 
a decision making or a reversal learning task (see Fig. 1). Another 
task that measures aspects of cognitive flexibility is the verbal flu-
ency task. This executive task involves the use of cognitive strate-
gies, inhibition of already mentioned words and the ability to shift 
to a new category.  
3. EFFECTS OF ATD ON FLEXIBLE BEHAVIOR 
A number of human studies have reported that ATD impairs 
cognitive flexibility [8-11, 31]. These results are supported by two 
animal studies that showed impaired cognitive flexibility after pre-
frontal 5-HT depletion [32, 33]. In contrast, other studies did not 
find effects of ATD on cognitive flexibility [34, 35]. Talbot et al. 
[35] showed that ATD improved decision making but did not affect 
reversal learning. Talbot et al. [35] hypothesized that personality 
characteristics play a decisive role in the effect of ATD on cogni-
tive performance. Support for this hypothesis is provided for exam-
ple by Cools et al. [36, 37]. These researchers showed that ATD 
modulated the amygdala activation in response to fearful faces as a 
function of self-reported threat sensitivity [37], and impaired moti-
vational guidance of goal-directed behavior as a function of the trait 
impulsivity [36]. Furthermore, neuroimaging studies failed to find 
effects of ATD on performance measures of cognitive flexibility 
(see Table 1). The absence of performance changes might be related 
to the adaptations that are needed to make a behavioral task suitable 
for fMRI, such as an increased number of trials.  
Cognitive inflexibility may be the result of an impairment of 
one of the subprocesses that underlie cognitive flexibility. Behav-
ioral studies showed that ATD does not affect response inhibition in 
healthy volunteers without a genetic vulnerability that is known to 
interact with ATD, such as a family history of depression or alco-
holism [38-41]. Although ATD does not seem to affect response 
inhibition, Walderhaug et al. [42] showed that ATD increased an 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The cognitive subprocesses that are involved in cognitive flexibility and paradigms that have been used to asses these cognitive processes. 
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impulsive response style on a continuous performance test. In con-
trast with the human data is a rat study that showed that the reversal 
deficit induced by prefrontal 5-HT depletion was due specifically to 
a failure to inhibit responding to the previously rewarded stimulus 
[33]. Previous studies showed that ATD did not impair but im-
proved focused attention during response interference [43, 44]. 
ATD impaired the processing of reward information. Rogers et al. 
[11] reported that ATD reduced discrimination between magnitudes 
of expected gain in a gambling paradigm. Cools et al. [37] found 
reduced reward-related speeding of response times in a cued-
reinforcement reaction time task. Interestingly, Roiser et al. [45] 
showed that this reduction was restricted to the volunteers homozy-
gous for the short allele (ss) of the 5-HTTLPR. Finger et al. [46] 
showed that ATD impaired the response to reward on a passive 
avoidance task. Additionally, this study showed that the effect of 
ATD on the processing of punishment information interacted with 
the 5-HTTLPR allele polymorphism: tryptophan depleted individu-
als homozygous for the long allele (ll) failed to appropriately use 
punishment information, but not the individuals homozygous for 
the short allele (ss).  
Although, some of the mentioned studies show that ATD im-
pairs cognitive flexibility and subprocesses important for cognitive 
flexibility, effects are often weak and inconsistent. The effect of 
ATD on cognitive flexibility as well as the influence of individual 
differences needs to be further established.  
4. THE EFFECT OF ATD ON BRAIN ACTIVATION DUR-
ING COGNITIVE FLEXIBILITY 
The above discussed behavioral studies are limited to making 
inferences about the psychological processes that are affected by 
ATD. The underlying brain mechanisms can be studied by using 
various neuroimaging techniques such as PET and fMRI. In a PET 
scan a radioactive tracer like 15O or 18F is built into a molecule like 
H2O and injected into the human body. By monitoring the positron 
emission decay of the tracer with a large amount of detectors the 
exact location of tracer can be determined. In this way it is possible 
to determine the spatial distribution of the tracer in the body, and 
makes it possible to estimate processes like blood flow or glucose 
consumption in specific areas of the brain (for review see [47, 48]). 
The early studies which combined PET with ATD mostly focused 
on psychiatric populations and measurements of the resting brain 
[49-52]. These studies showed that ATD especially influenced acti-
vation in the anterior cingulate cortex (ACC) and orbitofrontal cor-
tex. These changes strongly depend on individual mental health 
status, such as vulnerability to depression [53-58].  
Clear disadvantages of the PET technique are the invasive na-
ture and the relatively poor temporal resolution. Therefore, more 
recent studies have used fMRI which is not invasive and offers 
better temporal resolution. The fMRI technique is based on the 
different magnetic properties of oxygenated and deoxygenated he-
moglobin molecules, which lead to slightly different magnetic reso-
nance signal in blood carrying more or less oxygenated hemoglo-
bin. The general idea is that more active neural tissue leads to more 
blood flow to this tissue and to a higher percentage of oxygenated 
hemoglobin molecules, leading to a change in the so-called Blood-
Oxygen Level Dependent (BOLD) response. So, this BOLD re-
sponse can be used to distinguish more active neural tissue from 
less active tissue.  
The digital archive Pubmed (http://www.ncbi.nlm.nih.gov/sites/ 
entrez?db=pubmed) and the keywords ‘tryptophan depletion’, and 
‘fMRI’ or ‘PET’ were used to find studies that investigated the 
effect of ATD on brain activation during cognitive flexibility. In 
Table 1. The Studies that Investigated the Effect of ATD on Brain Activation During Tasks that Measure Cognitive Flexibility or Subprocesses 
that Underlie Cognitive Flexibility 
 
Study  
[reference number] 
Research 
technique 
Cognitive task Participants Effect of ATD 
on behavior 
 Effect of ATD 
 on the BOLD response 
Cognitive process 
under investigation 
Evers et al. 2005 [59] Functional MRI Reversal learning task Healthy volunteers 
(11 males) 
No effect ATD increased the response in 
the dorsomedial PFC (BA 8) 
Reversal learning 
Rubia et al. 2005 [60] Functional MRI Go/NoGo task Healthy volunteers 
(n=9, males and 
females) 
No effect ATD decreased the response in 
the right inferior/orbitofrontal 
PFC (BA 47, BA 45/6) and in-
creased the response in the supe-
rior and medial temporal cortices 
(BA 21/37). 
Response inhibition 
Evers et al. 2006 [61] Functional MRI Go/NoGo task Healthy volunteers 
(13 males) 
No effect ATD decreased the response in 
the dorsomedial PFC (BA 8).  
ATD did not change the response 
during response inhibition. 
Performance monitor-
ing 
Response inhibition 
Horacek et al. 2005 
[62] 
Functional MRI Stroop task Healthy volunteers 
(10 males, 10 
females) 
No effect ATD increased the response in 
the left inferior frontal (BA 47) 
and the right medial frontal cortex 
(BA 10). 
Response interference 
Evers et al. 2006 [43] Functional MRI Stroop task Healthy volunteers 
(15 females) 
ATD decreased 
the interference 
score  
ATD increased ACC (BA 32) 
activation in the 1st Stroop block 
the participants performed. 
Response interference 
Allen et al. 2006 [64] Functional MRI Verbal fluency task Healthy volunteers 
(8 males, 2 females) 
No effect ATD decreased the response in 
the precuneus (BA 7) and the 
medial frontal gyrus (BA 6) 
Cognitive flexibility 
Morris et al. 1999 
[51] 
PET Verbal fluency task Remitted depressed 
patients (8 males) 
No effect ATD reduced the response in the 
left ACC and the amygdala 
Verbal fluency rela-
tive to word repetition 
Smith et al. 1999 [52] PET Verbal fluency task  Remitted depressed 
patients (8 males) 
No effect The dorsal ACC showed modula-
tion of its activation by depressed 
mood. 
Verbal fluency 
ACC = Anterior Cingulate Cortex; ATD = Acute Tryptophan Depletion; BA = Brodmann Area; BOLD = Blood Oxygen Dependent Response; MRI = Magnetic Resonance Imaging; 
PET = Positron Emission Tomography. 
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total, six fMRI en two PET studies were found (see Table 1). In 
these studies either healthy volunteers or remitted depressed pa-
tients were tested using a counterbalanced placebo-controlled 
within-subject design. No studies were found that examined the 
effect of ATD on brain activation during cognitive flexibility in 
depressed patients or other patient groups.  
Reversal Learning 
Evers et al. [59] investigated the effect of ATD on probabilistic 
reversal learning in healthy volunteers. In this two choice discrimi-
nation task two abstract patterns were presented. Based on feed-
back, participants had to find out which of the two patterns was the 
most advantageous. During the task the stimulus-reward contin-
gency was reversed several times. The task was designed in such a 
way that brain activation related to 1) correct responses, 2) reversal 
switch errors (errors due to a reversal in reinforcement contingency 
after which the subject switched response) and 3) other errors, 
could be separated. ATD did not change performance. ATD in-
creased activation in the dorsomedial prefrontal cortex (dmPFC) 
when reversal switch errors (negative feedback followed by a be-
havioral switch) were contrasted with correct responses, and tended 
to increase this activation when other errors (negative feedback 
without behavioral switch) were contrasted to correct trials. No 
significant effect of ATD was found when reversal switch errors 
were contrasted with other errors. These results suggest that ATD 
affects reversal learning by changing the processing of negative 
feedback by modulation of the dmPFC. 
Response Inhibition 
Two fMRI studies [60, 61] investigated the effect of ATD on 
response inhibition during a Go/NoGo task in healthy volunteers. In 
the study by Rubia et al. [60] participants performed a choice reac-
tion time task, in which they had to press a button when they saw an 
arrow pointing left or right, and to withhold their response when the 
arrow pointed upwards. Although ATD did not affect performance, 
it decreased right inferior/orbitofrontal PFC activation and in-
creased activation in the superior and medial temporal cortices dur-
ing response inhibition. The authors concluded that these results 
provide evidence for a serotonergic modulation of the right inferior 
frontal cortex during response inhibition. In the study by Evers et 
al. [61] participants performed a Go/NoGo task in which a stream 
of letters was presented. The participants had to respond when the 
saw a Y preceded by an X, or an X preceded by a Y. When an X or 
Y was repeated, they had to withhold their response. Feedback was 
given after each response. The effect of ATD on performance moni-
toring (a response error followed by negative feedback) and re-
sponse inhibition was studied. ATD did not affect the reaction time 
on a trial after an error, but decreased the BOLD response in the 
dorsomedial PFC after an error. ATD did not affect response inhibi-
tion performance and the related brain activation. These two studies 
show different effects of ATD on brain activation during response 
inhibition. These differences might be due to task and design re-
lated differences, such as difficulty, feedback and gender of the 
participants. 
Response Interference 
Two fMRI studies investigated the effect of ATD on response 
interference during a Stroop task in healthy volunteers. Horacek et 
al. [62] tested performance during a Stroop task that consisted of a 
color naming, a word reading and an interference subtest. In addi-
tion, these participants were tested in the MRI scanner during a 
Stroop task that included blocks in which color congruent and 
blocks in which color incongruent words (e.g. “red” written in 
green ink) were presented. No effects of ATD were found on 
Stroop performance. ATD increased the BOLD response in the left 
inferior frontal cortex and the right medial frontal cortex during 
response interference. Evers et al. [43] tested the effect of ATD on 
response interference during a combined emotional and cognitive 
Stroop task. Participants performed two Stroop blocks in the MRI 
scanner in which congruent color, incongruent color and emotional 
words were semi randomly presented. They had to report the color 
of the ink by pressing one out of four response buttons. ATD de-
creased the interference score, which is an index for the reaction 
time on incongruent color relative to congruent color words. ATD 
increased the ACC activation when incongruent color words were 
compared to congruent color words in the first Stroop block. Fur-
thermore, ATD increased the BOLD response in the left precuneus 
and cuneus during congruent color words. These two studies 
showed that ATD does not impair performance by increasing re-
sponse interference. The differences in the effect of ATD on brain 
activation in these two studies could be related to methodological 
problems associated with the Horacek study: in the scanner, the 
participants only had to watch the colored words and did not have 
to indicate the color of these words with a response. 
Of interest is a study by Morgan et al. [63] that investigated the 
effect of TRP administration during a counting Stroop task in 
healthy volunteers. This task consisted of neutral (names of ani-
mals) and interference (names of numbers) blocks. Subjects were 
instructed to report the number of words. Interference was caused 
by a difference in the meaning of the words and the number of 
words presented (e.g. “two” was presented three times). TRP ad-
ministration did not affect performance. TRP administration de-
creased the activation in the post central, the inferior frontal and the 
angular cortex, and increased the activation in the precuneus and 
the posterior cingulate gyrus during response interference.  
Verbal Fluency 
In an fMRI study, Allen et al. [64] investigated the effect of 
ATD on two tasks that are known to engage PFC activation, namely 
a 2-back verbal working memory and a phonological verbal fluency 
task, in healthy volunteers. In both tasks, performance was un-
changed after ATD. In the n-back task, ATD decreased the activa-
tion in the superior frontal gyrus and increased the activation in the 
posterior cingulate gyrus. In the verbal fluency task, ATD de-
creased the activation in the precuneus and the medial frontal gyrus. 
In addition, two PET studies investigated the effect of ATD during 
verbal fluency in remitted depressed patients. Morris et al. [51] 
tested remitted patients during a paced word repetition and an or-
thographic verbal fluency task. ATD did not affect performance. 
Activity in the dorsal raphe nucleus and the habenula covaried posi-
tively, while activation in the septal region, amygdala and the orbi-
tofrontal cortex covaried negatively with plasma TRP levels. ATD 
reduced the activation in the left ACC and the amygdala in the ver-
bal fluency relative to the word repetition task. Smith et al. [52] 
used the same data set, but focused on the correlation between in-
duced depressed mood and brain activation. The dorsal ACC 
showed modulation of its activation by depressed mood when par-
ticipants performed a verbal fluency task, but not when they per-
formed the repetition task. When the participants were more de-
pressed after ATD, less activation was seen in the dorsal ACC. 
These studies showed that mood can be a confounder when the 
effect of ATD on cognition is studied. However, in the majority of 
studies, ATD did not induce depressed mood in healthy volunteers 
[19, 65], although small effects on mood have been reported [19, 
65-67], possibly related to a vulnerability for depression [49, 53-
58]. 
5. DISCUSSION 
The Effect of ATD on Cognitive Flexibility 
In the former section we have discussed the results of neuroi-
maging studies that investigated the effect of a transient lowering of 
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5-HT on cognitive flexibility and on cognitive subprocesses that are 
important for cognitive flexibility. Evers et al. [59] showed that 
ATD increased the activation in the dmPFC during reversal learn-
ing. Previous studies reported that depressed patients showed a 
catastrophic response to failure [68] or oversensitivity to negative 
feedback [69, 70]. Based on these studies and our own results, we 
hypothesized that ATD affects cognitive flexibility via negative 
feedback processing. 
However, this study does not exclude the possibility that ATD 
affects response inhibition, performance monitoring or response 
conflict during reversal learning. Excluding these possibilities 
would provide indirect evidence for our hypothesis. The results of 
the two studies that investigated the effect of ATD on response 
inhibition were inconclusive [60, 61]. Because the majority of be-
havioral studies did not show effects of ATD on response inhibition 
[37-41], ATD seems unlikely to impair cognitive flexibility by 
impairing response inhibition. The effect of ATD on performance 
monitoring (error followed by negative feedback) was examined in 
Evers et al. [61]. This study showed that ATD changed brain acti-
vation during performance monitoring. Since EEG studies did not 
find an effect of ATD (Evers et al. unpublished data) or the first 
line antidepressant mirtazipine [71] on the error-related negativity 
(an error component that is seen before feedback is received), this 
might suggest that the effect of ATD on performance monitoring is 
caused by an effect on the processing of negative feedback. 
Horacek et al. [62] and Evers et al. [43] investigated the effect of 
ATD on response interference during a Stroop task. Based on the 
results of behavioral studies, that showed that ATD improved or did 
not affect Stroop interference [34, 62, 72-75], and the methodologi-
cal problems with the Horacek et al. [62] study, we suggest that 
ATD is unlikely to impair reversal learning by an increase in re-
sponse interference. 
To conclude, these studies might suggest that ATD affects cog-
nitive flexibility by changing the processing of negative feedback, 
rather than by impairing response inhibition, the response to an 
error or an increase in response conflict. However, this hypothesis 
is still premature and strong evidence is up till now lacking. Fur-
thermore, since genetic makeup seems important for the effect of 
ATD on the processing of negative information [46], future studies 
should unravel the association between the effect of ATD on nega-
tive feedback modulated by the dorsomedial PFC and the types of 
alleles for the 5-HTTLPR.  
Previous research showed that ATD affects the processing of 
reward information: participants are less motivated by properties of 
stimuli predictive of reward [37, 45], make more failures to respond 
to a rewarded stimulus [46] and show reduced discrimination be-
tween different magnitudes of reward [11]. The effects of ATD on 
reversal learning [59] might have been affected by an effect of ATD 
on reward. Firstly, reward plays a general role in cognitive flexibil-
ity: behavior is adjusted in order to regain positive feedback or 
reward. Secondly, in the effect of ATD on dmPFC activation during 
reversal learning [59] reward was involved: reversal switch errors 
(followed by negative feedback) were compared with correct re-
sponse (followed by positive feedback). When considering the ef-
fects of ATD on rewards during cognitive flexibility it is important 
to note the majority of studies so far have related reward with the 
dopaminergic system [76-78]. 
Interactions of Low 5-HT with other Neurotransmitters 
ATD might interact with other neurotransmitter systems. It has 
been shown that 5-HT acts through several 5-HT receptor and 
modulates not only the release of acetylcholine, noradrenalin, glu-
tamate and GABA [79], but also that of dopamine in all three major 
dopaminergic pathways [for review see 80]. It has been suggested 
that the improvement of focused attention during Stroop perform-
ance after ATD might be the result of increased DA [43]. However, 
effects of ATD on the DA system have not been found so far [81]. 
Booij et al. [82] reported that ATD did not affect the plasma DA 
metabolite homovanillic acid (HVA), while 5-HIAA levels were 
significantly reduced. Young et al. [83] showed that tyrosine and 
the catecholamine metabolites were unchanged after ATD in pri-
mates. Carpenter et al. [84] showed that despite a rise in tyrosine, 
no change in the amount of the major DA metabolite HVA was 
found after ATD in human cerebrospinal fluid (CSF). Lieben et al. 
[85] examined the effects of ATD with a gelatin collagen protein 
(CP) mixture on the levels of 5-HT, 5-HIAA, DA and the DA me-
tabolite DOPAC (3,4-dihydroxyphenylacatic acid) in the rat brain. 
They showed that after ATD the levels of 5-HT and 5-HIAA were 
significantly reduced in the striatum, the hippocampus and the cor-
tex, whereas levels of DA and DOPAC were unchanged in these 
areas. Another system that might be affected by ATD is the opioid 
system, since ATD was found to abolish the analgesic effect of 
morphine in human volunteers [86].  
The Dissociation Between the Effect of ATD on Brain Activa-
tion and Performance 
In most of the neuroimaging studies discussed in this review ar-
ticle, ATD resulted in changed brain activation without affecting 
performance (see Table 1). We will discuss five possible explana-
tions for this dissociation.  
Firstly, there is no effect of ATD on cognitive flexibility and 
the differential brain activation seen during ATD has no significant 
association with the performed task. This explanation is based on 
the inconsistent effects of ATD on cognitive flexibility. The dis-
cussed results, however, show that effects of ATD on brain activa-
tion are only seen during specific cognitive events, such as after 
making a reversal error. Therefore this explanation is unlikely to be 
correct.  
Secondly, the effect of ATD on performance might be hidden 
because of learning effects. In the reviewed studies cognitive tasks 
are often well practiced: the participants performed the task during 
a practice, a depleted and a balanced session. Previous research 
showed that ATD impairs performance on a reversal learning task 
when the task was novel to the subjects [8, 9].  
Thirdly, the cognitive tasks used measure a combination of 
cognitive subprocesses, while previous studies suggest that not all 
of these processes are changed by ATD. For example, during a 
reversal switch in a reversal learning task the following subproc-
esses are involved: feedback processing, learning new stimulus-
reward associations, inhibition of the response related to the previ-
ous stimulus-reward associations and behavioral adaptation. Be-
cause negative feedback processing is only one of the processes 
involved in reversal learning it is possible that changes in negative 
feedback processing do not show in the behavioral outcome meas-
ures.  
Fourthly, it is possible that ATD influences the cognitive strat-
egy the participants used to successfully perform the tasks. Partici-
pants might need to recruit more or less effort, or might need to 
recruit other brain structures to reach the same level of perform-
ance. As a result brain activation patterns change, but performance 
is comparable. For example, Dibbets et al. [87] showed that chil-
dren with specific language impairment recruit other brain regions 
than children without this impairment during a task switching para-
digm, while performance is comparable between these two groups.  
Fifth and finally, neuroimaging might capture aspects of cogni-
tion that performance measures can not. Neuroimaging studies 
show brain activation patterns that underlie cognitive processes, 
while performance measures show the behavioral outcome of these 
brain mechanisms. Performance measures like reaction times and 
accuracy might therefore be imperfect measures of cognition. Our 
results might add to the suggestion that the BOLD response is more 
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sensitive to detect changes in cognition than performance measures 
[88].  
Importantly, the second until fourth explanation support the 
fifth explanation. If the second explanation is correct, neuroimaging 
is able to show effects of ATD on reversal learning, while learning 
effects prevented effects of ATD on performance. If the third ex-
planation is correct, neuroimaging is able to show effects of ATD 
on performance monitoring in a reversal learning and Go/NoGo 
task while performance measures were not able to dissociate be-
tween the effects of ATD on different cognitive subprocesses. If the 
fourth explanation is correct, neuroimaging is able to show that 
ATD leads to brain activation changes due to changes in effort or 
cognitive strategy, while performance outcomes are unchanged.  
It remains to be tested by future research which explanation is 
correct. Importantly, all explanations, except the first, show the 
importance of neuroimaging methods for cognitive research. 
The Influence of Biological and Psychological Factors 
Previous studies showed that the effects of ATD on cognition 
and the related brain activation are influenced by psychological and 
biological factors. ATD modulated the amygdala activation in re-
sponse to fearful faces as a function of self-reported threat sensitiv-
ity [36] and impaired motivational guidance of goal-directed behav-
ior on a cued-reinforcement task as a function of the trait impulsiv-
ity [37]. Previous research showed interactions between the 5-
HTTLPR genotype and the effect of ATD on motivational behavior 
and passive avoidance [45, 46]. In addition, our own group con-
firmed the influence of biological factors on the effect of ATD [89]. 
The effect of ATD on facial recognition was studied in healthy 
women with and without a family history of depression. This study 
showed that the mood response ATD induced in women with a 
family history of depression, leads to more interference from nega-
tive faces and a stronger amygdala response. These studies indicate 
the importance of individual difference in ATD research and sug-
gest that is it important for future research to control for biological 
and psychological factors that have shown to influence the effect of 
ATD.  
This suggestion is supported by ATD studies that showed con-
tradictory findings. For example, Rogers et al. [90] investigated the 
effect of ATD on a decision gambling task and showed that ATD 
decreased the tendency to choose the more likely outcome. Directly 
opposite are the results of Talbot et al. [35] who used the exact 
same task but showed that ATD increased the tendency to choose 
the more likely outcome. Based on the very similar designs of these 
studies and almost identical demographic characteristics of the 
participants, Talbot et al. [35] suggest that the different results are 
related to intrinsic trait characteristics of the participants. They 
therefore conclude that the contrast between these studies suggests 
the need for future ATD studies to control for personality, family 
history and genetic factors. 
6. CONCLUSION  
In conclusion, it can be said that the use of fMRI to determine 
the underlying brain mechanisms involved in the effect of acutely 
lowering serotonin levels by means of ATD have yielded intriguing 
and sometimes puzzling results. The studies performed so far have 
suggested that 5-HT plays a role in cognitive flexibility, but impor-
tant modulating factors such as personality characteristics, genetic 
vulnerability factors and gender should be carefully controlled be-
fore strong conclusions can be drawn. The studies reviewed here 
provided strong arguments for the execution of experiments in 
which sources of individual variability are taken into consideration 
and even are the primary research question. Future studies should 
especially be devoted to differential vulnerability factors. Individual 
differences in genes that are involved in the 5-HT metabolism such 
as 5-HT transporter, tryptophan hydroxylase-2 and the different 5-
HT receptor genes should be taken into account to explain the com-
plicated relation between 5-HT challenge tests such as ATD and 
cognitive functions such as cognitive flexibility. A further step 
could be to specifically look at gene expression and relate this to 
vulnerability to changes in 5-HT availability. As was stated before, 
the 5-HT system strongly interacts with other neurotransmitter sys-
tems, of which the DA system is possibly one of the most interest-
ing from the perspective of psychiatric disorders. Therefore, future 
studies should also include genes which are involved in DA me-
tabolism such as the catechol-O-methyl transferase (COMT) gene 
and genes that are more generally involved in monoamine metabo-
lism, such as the monoamine oxidase A gene. Both mentioned 
genes have also been extensively linked to cognitive function and 
psychiatric disease. In our view a multidisciplinary approach in 
which multiple genes and other individual risk factors are taken into 
account would be most fruitful in making progression in this com-
plicated area of research. 
ABBREVIATIONS 
ACC = Anterior Cingulate Cortex 
ATD = Acute Tryptophan Depletion 
BA = Brodmann Area 
BBB = Blood-Brain Barrier 
BOLD = Blood-Oxygen Level Dependent 
CSF = Cerebrospinal Fluid 
CNS = Central Nervous System 
COMT = Catechol-O-Methyl Transferase 
CP = Collagen Protein 
DA = Dopamine 
DOPAC = 3,4-Dihydroxyphenylacatic Acid 
fMRI = Functional Magnetic Resonance Imaging 
HVA = Homovanillic Acid 
OCD = Obsessive-Compulsive Disorder 
ID/ED  = Intra-/Extra-Dimensional  
LNAA = Large Neutral Amino Acids 
MRI = Magnetic Resonance Imaging 
PET = Positron Emission Tomography 
PFC = Prefrontal Cortex 
TRP = Tryptophan 
5-HIAA = 5-Hydroxyindoleacetic Acid 
5-HT = 5-Hydroxytryptamine, Serotonin 
5-HTP = 5-Hydroxytryptophan 
5-HTTLPR = Serotonin Transporter (5-HTT) Gene-Linked Pro-
motor Region 
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